Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
Conditions: Nasal Cavity Cancer; Paranasal Sinus Cancer; Camrelizumab; Induction Chemotherapy; Intensity Modulated Radiotherapy; Concurrent Chemotherapy Intervention: Drug: camrelizumab Sponsor: Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Nasal Cavity and Paranasal Sinus Cancer | Research